Peter Attia on Longevity Medication: What He Has Said About His Protocol

Who Is Peter Attia and Why His Medication Views Matter

Peter Attia is a physician who trained in general surgery at Johns Hopkins Hospital and later studied at the National Cancer Institute before pivoting entirely to longevity-focused clinical practice. He founded Attia Medical PC (now Early Medical) to apply what he calls "Medicine 3.0," a framework that treats aging itself as a modifiable disease rather than an inevitability.

Why Clinicians Pay Attention

His influence extends beyond typical health-influencer territory. Attia reads and discusses primary literature at a level unusual for public-facing physicians. His podcast guests include researchers who designed the trials he references (Nir Barzilai on TAME, Matt Kaeberlein on rapamycin in dogs). When Attia changes his mind about a drug, the shift reaches millions of listeners and often drives patient questions in endocrinology and primary-care offices within days.

The Transparency Norm He Set

Few MDs publicly disclose their personal lab values, medication doses, and decision-making rationale the way Attia does. This transparency makes his protocol a useful case study, but it also requires careful separation between what he states as personal practice versus what he recommends clinically.

Rapamycin (Sirolimus): The Centerpiece mTOR Intervention

Attia has discussed rapamycin more extensively than any other longevity-focused medication. He has stated on multiple episodes of The Drive that he takes a pulsed weekly dose of sirolimus, distinguishing this from the daily immunosuppressive dosing used in transplant medicine.

Dose and Schedule (As Publicly Stated)

On episode 224 of The Drive (2023), Attia described using rapamycin at approximately 5-6 mg once per week, cycled with periodic breaks. He frames this as targeting mTOR complex 1 (mTORC1) inhibition while attempting to spare mTORC2, which mediates some of the immunosuppressive effects seen at higher continuous doses.

The Evidence He Cites

Attia frequently references the ITP (Interventions Testing Program) mouse data showing lifespan extension of 9-14% with rapamycin initiated even at 20 months of age [1]. He also discusses the Mannick et al. 2014 trial in Science Translational Medicine (N=218), which demonstrated that low-dose mTOR inhibition improved influenza vaccine response in elderly subjects rather than suppressing immunity [2].

His Stated Caveats

Attia has been explicit that rapamycin for longevity remains off-label and lacks large human RCT evidence. He monitors his own CBC, lipid panel, fasting glucose, and oral health (aphthous ulcers being a known side effect) and has mentioned dose adjustments based on lab changes.

Metformin: The Drug He Stopped Taking

Attia's reversal on metformin is one of the most-discussed medication decisions in the longevity community. He initially took metformin based on observational data suggesting reduced all-cause mortality in diabetics on metformin versus non-diabetic controls (Bannister et al., 2014) [3].

Why He Discontinued

The key moment, by his own account, came from data presented at scientific conferences showing metformin blunts the skeletal muscle hypertrophy response to resistance training. The MASTERS trial (Walton et al., Aging Cell, 2019, N=94) demonstrated that metformin attenuated muscle protein synthesis and fiber hypertrophy in older adults performing progressive resistance exercise [4].

His Current Position

Attia has stated that for someone who prioritizes lean mass preservation (as he does), the exercise-blunting effect creates a net-negative trade-off given the modest and still-unproven longevity signal. He has noted exceptions: patients with frank insulin resistance who are not exercising consistently may still benefit. This nuance often gets lost in headlines claiming he "rejected" metformin entirely.

Aggressive Lipid Management: PCSK9 Inhibitors and the apoB Philosophy

No aspect of Attia's clinical philosophy has been more consistent than his aggressive approach to apolipoprotein B (apoB) reduction. He treats apoB as the single best predictor of atherosclerotic cardiovascular disease (ASCVD) risk and targets concentrations below the 5th percentile.

The Pharmacotherapy Stack

Attia has disclosed taking a PCSK9 inhibitor (he has referenced both evolocumab and alirocumab in educational contexts). He views statins, ezetimibe, and PCSK9 inhibitors as a tiered toolkit and has stated he personally uses combination therapy to reach his target. A 2017 meta-analysis of 26 RCTs (N=170,000+) published in The Lancet confirmed a log-linear relationship between LDL-C reduction and ASCVD event reduction, with no lower threshold identified [5].

Mendelian Randomization as His Philosophical Anchor

Attia's conviction comes heavily from Mendelian randomization studies. He frequently cites Ference et al., JAMA, 2012, showing that lifelong genetic exposure to lower LDL-C via PCSK9 loss-of-function variants produces a 3:1 event-reduction ratio compared to later pharmacological intervention [6]. His argument: starting lipid-lowering therapy in one's 30s or 40s captures more of that "area under the curve" benefit.

The Attia Lipid Decision Framework

Attia's publicly described approach can be summarized as a three-step algorithm he has outlined across podcast episodes 203, 210, and 242:

1. Measure apoB directly (not calculated LDL-C). Target: <60 mg/dL for most patients, <40 mg/dL for those with strong family history or elevated Lp(a).
2. Start with the lowest-side-effect agent first. For many patients, this means ezetimibe (10 mg) or a low-dose statin rather than high-intensity statin monotherapy.
3. Add a PCSK9 inhibitor early if the target requires >50% apoB reduction, rather than pushing statin dose to maximum and accepting myalgia.

This inverts the standard guideline algorithm (which begins with high-intensity statin and adds sequentially) and prioritizes tolerability and adherence over cost.

Testosterone Replacement Therapy

Attia has acknowledged using testosterone replacement on multiple occasions, though he discusses it with less pharmacological detail than rapamycin or lipid agents. He has framed TRT as part of hormone optimization for a male in his 50s whose endogenous production has declined.

Clinical Context He Provides

On The Drive, Attia has referenced maintaining total testosterone in the upper-normal range (roughly 800-1,000 ng/dL) and monitoring hematocrit, PSA, and estradiol. He has discussed the Testosterone Trials (TTrials, 2016, N=790), which showed improvements in sexual function, walking distance, and mood in hypogonadal men over 65 receiving testosterone gel for 12 months [7].

What He Does Not Disclose

Attia has not publicly specified his exact formulation (cypionate vs. Enanthate vs. Gel), dose, or injection frequency. He treats this as a private clinical decision made with his own physician, a boundary he has explicitly drawn.

Medications He Has Discussed But Not Confirmed Taking

Several compounds appear frequently in Attia's educational content without clear confirmation of personal use.

GLP-1 Receptor Agonists

Attia has dedicated entire podcast episodes to semaglutide and tirzepatide. He views them as the most important pharmacological development in cardiometabolic medicine in decades. In the SELECT trial (N=17,604), semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight/obesity and established CVD [8]. Attia has not confirmed personal use but has stated he prescribes GLP-1 RAs to appropriate patients.

Aspirin (Low-Dose)

Attia has discussed the ASPREE trial (N=19,114) findings that low-dose aspirin did not extend disability-free survival in healthy elderly adults and increased bleeding risk [9]. He has stated this influenced his decision-making for primary prevention patients but has not disclosed whether he personally takes aspirin.

SGLT2 Inhibitors

He has discussed empagliflozin's cardiovascular and renal benefits (EMPA-REG OUTCOME, N=7,020) [10] in educational contexts. No confirmed personal use.

The Exercise-as-Medication Philosophy

Attia positions exercise as a more powerful intervention than any pharmaceutical, a point he makes repeatedly and quantifies. He cites a 2022 meta-analysis in the British Journal of Sports Medicine showing that individuals in the top quartile of cardiorespiratory fitness have a 5x reduction in all-cause mortality compared to the bottom quartile, an effect size larger than any single drug intervention [11].

His Personal Protocol

He has detailed performing four Zone 2 sessions per week (45-60 minutes, nasal breathing, lactate <2 mmol/L) plus three strength-training sessions emphasizing grip strength, hip hinging, and carrying. He frames this as the "centenarian decathlon" preparation: training specifically for the physical tasks he wants to perform at age 100.

Interaction With Pharmacotherapy

This exercise emphasis directly influenced his metformin discontinuation. It also informs his rapamycin scheduling, as he has mentioned timing doses away from hard training sessions based on theoretical concerns about mTORC1 suppression impairing muscle protein synthesis in the post-exercise window.

What Attia Gets Right (and Where Caution Applies)

Strengths of His Approach

Attia reads primary literature, changes his mind publicly when data shifts, and distinguishes personal experimentation from clinical recommendation. His apoB-lowering approach is directionally supported by Mendelian randomization and large RCTs, even if the specific targets he pursues are more aggressive than current AHA/ACC guidelines specify.

Where Listeners Should Exercise Caution

Rapamycin lacks a phase III longevity trial in humans. Pulsed dosing protocols are based on pharmacokinetic reasoning and animal data, not randomized human evidence. Attia acknowledges this but his audience may not internalize the distinction between "plausible intervention a physician takes on himself" and "evidence-based recommendation."

His approach also reflects access to resources most patients do not have: quarterly comprehensive bloodwork, direct physician relationships with researchers, and out-of-pocket medication costs that insurance would not cover for off-label longevity indications.

How This Relates to Patients Considering Longevity Pharmacotherapy

Patients who arrive at a clinician's office citing Peter Attia typically want to discuss one of three things: rapamycin, aggressive apoB lowering before age 50, or metformin discontinuation. Understanding what Attia has actually said (versus internet summaries) equips clinicians to have productive conversations grounded in shared evidence.

The most defensible starting point for most patients remains cardiovascular risk reduction via apoB measurement and appropriate lipid-lowering therapy, a position both Attia and mainstream cardiology guidelines support, though they differ on timing and intensity.

Patients interested in rapamycin should understand they are accepting unknown long-term risk in exchange for a theoretical benefit extrapolated from model organisms. Attia himself frames this as a calculated personal gamble, not a blanket recommendation. His target sirolimus trough level (per public statements) is below 5 ng/mL, substantially lower than transplant protocols.